louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT00738712: Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies for Vascular, Abdominal, and Pelvic Exams
Official title: Refinement and Assessment of New Magnetic Resonance Imaging (MRI) Technologies for Vascular, Abdominal, and Pelvic Exams
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy
Keywords: Vascular MRI
Abdominal MRI
Pelvic MRI
Breast MRI
Magnetic Resonance Imaging (MRI)
Lead sponsor: University of Michigan
Sponsor class: OTHER
Collaborators: name: General Electric
name: Philips Healthcare
First posted: 2008-08-20
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: DIAGNOSTIC

Brief summary: This study is being done to assess new Magnetic Resonance Imaging (MRI) technologies designed to improve MRI examinations of the vascular structures, abdomen, and pelvis regions.

Detailed description: This study is being done to assess new Magnetic Resonance Imaging (MRI) technologies such as new hardware or software designed to improve MRI examinations of the vascular structures, abdomen, and pelvis regions. Software and hardware are always being improved, new machines replace old machines, software is updated and improved as well as devices used to produce better MRI images.

Eligibility criteria: Inclusion Criteria:

* male or non-pregnant female patient
* 18 years or older
* any ethnic background
* presenting to MRI for a clinically-ordered chest MRI exam.

Exclusion Criteria:

* Patients, who have electrically, magnetically or mechanically activated implants such as heart pacemaker, magnetic surgical clips, prostheses or implanted neurological stimulator.
* Pregnant patients or patients who are lactating.
* A patient who is claustrophobic

Primary outcomes:
measure: Evaluation of new software in MRI vascular imaging
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Ann Arbor
country: United States
facility: University of Michigan Health Center
state: Michigan
Study officials:
affiliation: University of Michigan
name: William Masch, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01325012: Ultrasound-Guided Continuous Sciatic Nerve Blocks: Popliteal Versus Subgluteal Catheters
Official title: Ultrasound-Guided Continuous Sciatic Nerve Blocks: Popliteal Versus Subgluteal Catheters
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Foot Surgery
Keywords: Pain
Surgery
Catheter
Nerve Block
Popliteal
Subgluteal
Sciatic
UCSD
Moderate-to-severe pain
Perineural Catheter
Orthopedic Surgery
foot surgery surgery
sciatic perineural catheter
age =>18
Lead sponsor: University of California, San Diego
Sponsor class: OTHER
First posted: 2011-03-29
Enrollment: 2
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To determine the relationship between perineural catheter location along the sciatic nerve (popliteal versus subgluteal placement) and infusion effects for ultrasound-guided continuous sciatic nerve blocks.


Eligibility criteria: Inclusion Criteria:

* undergoing foot surgery with a sciatic perineural catheter for postoperative analgesia
* spending the first postoperative night hospitalized
* age 18 years or older

Exclusion Criteria:

* pregnancy
* inability to communicate with the investigators and hospital staff
* incarceration
* clinical neuropathy in the surgical extremity

Primary outcomes:
measure: Muscle Strength (MVIC) of the hamstring muscles
timeFrame: 08:00-09:00 morning after surgery as a percentage of baseline
Secondary outcomes:
measure: Sensory Effect
timeFrame: 08:00-09:00 morning after surgery
measure: Pain Scores
timeFrame: from leaving the PACU until 08:00 the morning after surgery
measure: Sleep Disturbances
timeFrame: recorded at 08:00-09:00 the morning after surgery for the previous night
measure: Total Infusion
timeFrame: recorded at 08:00-09:00 the morning following Surgery
measure: Anesthetic Leakage
timeFrame: recorded at 08:00-09:00 the morning following Surgery
measure: analgesic consumption
timeFrame: end of PACU stay until 08:00-09:00 the morning following surgery
Other outcomes:
Locations:
city: La Jolla
country: United States
facility: UCSD Medical Center, Thornton
state: California
city: San Diego
country: United States
facility: UCSD Medical Center Hillcrest
state: California
Study officials:
affiliation: University of California, Department of Anesthesiology
name: Brian M Ilfeld, M.D., M.S.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06142812: Gamification in the University Classroom.
Official title: Gamification in the Classroom: Kahoot as a Tool for University Teaching Innovation.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: University Student
Lead sponsor: University of Jaén
Sponsor class: OTHER
First posted: 2023-11-22
Enrollment: 74
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This article aims to demonstrate the results of a study on the implementation of Kahoot as a gamification tool in university education. The objectives of this article are: to promote teaching by integrating the use of Kahoot to motivate students and increase their degree of interest and know the students' abilities. opinions on the implementation of this Gamification tool to teach grammar. The study uses a quasi-experimental research design over a four-month period observing variables such as attention, concentration and creativity, as well as social and personal skills.


Eligibility criteria: Inclusion Criteria:

* University participants who were enrolled in the second year of the Physiotherapy Degree at the University of Jaén will be included.
* Study Period: Those participants who were available and participated in the study from September to December 2022 were considered.

Exclusion Criteria:

* University students who did not provide informed consent according to the study's ethical guidelines.
* Enrolled in at least one subject from another academic year.

Primary outcomes:
measure: D2 test
timeFrame: Up to twelve weeks
measure: Creative intelligence test (CREA)
timeFrame: Up to twelve weeks
measure: The ability subscale of the SEQ developed by Kember & Leung
timeFrame: Up to twelve weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Jaén
country: Spain
facility: Agustín Aibar Almazán
Study officials:
References:
Clinical trial NCT01891812: Nitrous Oxide Analgesia Vaso-occlusive Crisis
Official title: Nitrous Oxide for Analgesia in Sickle Cell Vaso-occlusive Crisis
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Sickle Cell Disease
Vaso-occlusive Crisis
Keywords: Sickle cell disease
Vaso-occlusive crisis
Nitrous oxide
Emergency department
Lead sponsor: Columbia University
Sponsor class: OTHER
First posted: 2013-07-03
Enrollment: 5
Sex: ALL
Minimum age (years): 8
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients who have sickle cell VOC are usually treated with opioids, such as morphine. However, this current way of treating them has not improved the health, medical outcomes, or rates of hospitalizations. In addition, since VOC can happen very frequently over a long period of time, giving opioids over and over again can cause both short-term and long-term problems. Nitrous oxide (N2O) is a way of treating pain that may provide a better alternative to repeatedly giving opioids over long periods of time. N2O has been shown to provide up to 3 hours of pain relief in inpatient patients with VOC whose pain did not improve with morphine infusions, and is used extensively in France, where almost half of 85 pediatric emergency departments use nitrous oxide to treat children with VOC whose pain did not get better with standard treatment with morphine. However, pain relief which N2O provides in the acute setting has not been well described. Therefore, the purpose of our study is to describe how well N2O can relieve the pain in patients with SCD who present to the emergency department and are experiencing a VOC.


Eligibility criteria: Inclusion Criteria:

* Patients with sickle cell disease
* Ages 8 to 18, inclusive
* Present to the pediatric emergency department with VOC and whose pain scores remain greater than or equal to 7/10 on the NRS after initial standard treatment (i.e. IV fluids, morphine and NSAIDs).

Exclusion Criteria:

* life-threatening illness as determined by attending clinician
* developmental delay
* altered level of consciousness
* any contraindications to receiving N2O
* foster children and wards of the state

Primary outcomes:
measure: Pain Score
timeFrame: Up to 4 hours
Secondary outcomes:
measure: Duration of Analgesia
timeFrame: Up to 4 hours
Other outcomes:
measure: Number of Participants With Peripheral Neuropathies
timeFrame: 8 weeks
measure: Number of Participants With Macrocytic Anemia
timeFrame: 8 weeks
Locations:
city: New York
country: United States
facility: New York Presbyterian Morgan Stanley Children's Hospital
state: New York
Study officials:
affiliation: Columbia University
name: Daniel S Tsze, MD, MPH
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00550212: Study Evaluating Oral Administrations of HKI-272 in Healthy Male Subjects
Official title: An Open-Label, Single-Dose Study of the Mass Balance and Metabolic Disposition of Orally Administered [14C]-Labeled HKI-272 in Healthy Male Subjects
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Keywords: healthy subjects
Lead sponsor: Puma Biotechnology, Inc.
Sponsor class: INDUSTRY
First posted: 2007-10-29
Enrollment: 6
Sex: MALE
Minimum age (years): 18
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the mass balance and metabolic distribution of C14-labeled HKI-272 in healthy male subjects.


Eligibility criteria: Inclusion Criteria:

* Healthy male subjects, aged 18 to 50 years.

Exclusion Criteria:

* Female subjects

Primary outcomes:
measure: Mass balance, metabolic distribution, PK
timeFrame: 10 days
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Biotechnology
name: Puma
role: STUDY_DIRECTOR
References:
Clinical trial NCT00275912: Efficacy, Safety, and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
Official title: A 24-week Prospective Open-label Multicenter Study to Evaluate the Effect on Seizure Frequency, Safety and Tolerability of Oxcarbazepine Monotherapy in Children With Partial Seizures
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Epilepsy, Partial Seizures
Lead sponsor: Novartis
Sponsor class: INDUSTRY
First posted: 2006-01-12
Enrollment: 60
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study is aimed to collect additional data regarding the efficacy in reducing the frequency of partial seizures, as well as the safety and tolerability, of oxcarbazepine monotherapy in children.


Eligibility criteria: Inclusion Criteria:

* males and females, 6 months - 17 years of age;
* diagnosis of epilepsy, partial seizures;
* ineffective or intolerable present therapy with 1 antiepileptic drug, or none of previous antiepileptic therapy

Exclusion Criteria:

* progressive lesion of brain revealed by CT/MRI that performed no earlier than 2 years prior to screening;
* non-epileptic seizures;
* drug or alcohol dependence during a year prior to screening;

Other protocol-defined inclusion/exclusion criteria may apply.

Primary outcomes:
measure: Epileptic activity at electroencephalography in rest
measure: Flash light and hyperventilation test with electroencephalography
measure: Frequency of epileptic episodes according to patient's diary
measure: Electrocardiogram analysis for rhythm and conduction
measure: Blood test for sodium, hepatic enzymes and blood cells
Secondary outcomes:
measure: Tolerability and safety of 24 week's treatment with oxcarbazepine monotherapy in children with partial seizures
measure: Rate of patients with total and partial control of epilepsy
measure: Rate of patients requiring additional antiepileptic drugs
Other outcomes:
Locations:
city: Ekaterinburg
country: Russian Federation
facility: Regional Pediatric Clinical Hospital №1 EkaterinburgRegional Pediatric Clinical Hospital №1
city: Moscow
country: Russian Federation
facility: Moscow Scientific Research Institute of Pediatrics and Pediatric Surgery
city: Moscow
country: Russian Federation
facility: Russian State Medical University clinically based on Russian Pediatric Clinical Hospital
city: Moscow
country: Russian Federation
facility: Scientific-practical centre of children treatment suffering from craniofacial malformation and congenital pathology of nervous system
city: St Petersburg
country: Russian Federation
facility: St. Petersburg State Pediatrics Medical Academy
Study officials:
affiliation: Novartis Pharmaceuticals
name: Novartis Pharmaceuticals
role: STUDY_CHAIR
References:
Clinical trial NCT04628312: Foot Plantar Pressure Changes After Plantar Dry Needling
Official title: Standing Plantar Pressure Changes After Plantar Dry Needling in Flexor Digitorum Brevis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Myofascial Pain Syndrome
Foot Diseases
Lead sponsor: Mayuben Private Clinic
Sponsor class: OTHER
First posted: 2020-11-13
Enrollment: 18
Sex: ALL
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The aim of this clinical trial is to check the effects of dry needling in the Flexor digitorum Brevis.

Twenty healthy subjects wil be recruited for a quasi-experimental study. Participants will be from 18 to 40 years old, not obese. Participants will be measured before and after bilateral dry neddling in Flexor digitorum Brevis. The investigators will measure static footprint variables. The footprint variables will be divided in bilateral rear foot, bilateral midfoot, bilateral fore foot.


Eligibility criteria: Inclusion Criteria:

* Flat foot grade II or II with
* Must have latent trigger point in Flexor Brevis Digitorum muscles

Exclusion Criteria:

* Previous lower extremities surgery.
* History of lower extremities injury with residual symptoms (pain, "giving-away" sensations) within the last year.
* Leg-length discrepancy more than 1 cm

Primary outcomes:
measure: Variables of plantar pressures with platform before dry puncture
timeFrame: Through study completion, an average of 1 week
measure: Variable footprint plantar surface with platform before dry puncture
timeFrame: Through study completion, an average of 1 week
measure: Variables of plantar pressures with platform after dry puncture
timeFrame: Through study completion, an average of 1 week
measure: Variable footprint plantar surface with platform after dry puncture
timeFrame: Through study completion, an average of 1 week
Secondary outcomes:
Other outcomes:
Locations:
city: San Sebastián De Los Reyes
country: Spain
facility: Mayuben Clinic
state: Madrid
Study officials:
References:
Clinical trial NCT03511612: Comparison of the Ankle-Brachial Index Measurement Using a Specific Oscillometric Device vs. the Doppler Method
Official title: Comparison of the Ankle-Brachial Index Measurement Using a Specific Oscillometric Device vs. the Doppler Method
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Peripheral Arterial Disease, Ankle Brachial Index, Doppler
Lead sponsor: University Hospital, Limoges
Sponsor class: OTHER
First posted: 2018-04-30
Enrollment: 51
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: DIAGNOSTIC

Brief summary: Several methods are available to measure ankle brachial index (ABI) non-invasively. A recent scientific statement of the AHA considers the Doppler method as the reference. However because Doppler devices are not widely available in primary care, several attempts have been made to propose alternative methods, among whom oscillometric methods (automatic blood pressure machines) have attracted most attention.

We hypothesize that:

- the diagnostic characteristics (i.e. sensitivity, specificity and AUC) of the oscillometric method would be very good as compared to the Doppler method.

the oscillometric method would have better intra- and inter-observer reproducibilities as compared to the Doppler method.


Eligibility criteria: Inclusion Criteria:

Patients referred with the suspicion of PAD, either because of:

* symptoms in favor of intermittent claudication or more atypical pain when walking, or
* asymptomatic individuals with the presence of at least 2 cardiovascular risk factors among the following :

  * Men \> 60 years or women \> 65 years
  * Regular cigarette smoking \>10 years, either current or in the past
  * Treated Type-2 diabetes \>5 years or Type-1 diabetes \>20 years
  * Treated hypertension
  * High blood cholesterol (either total-C \>240 mg/dl or LDL-C \>160 mg/dl) or treated by statins or other lipid-lowering agents
  * Documented history of coronary artery disease (history of PCI or CABG, or previous myocardial infarction, or CAD documented by coronary angiography)
  * Documented history of ischemic stroke

Exclusion Criteria:

* Patients with revascularized PAD
* Patients with critical limb ischemia or leg/foot ulcers
* Cardiac arrhythmia: Atrial fibrillation, atrial flutter, frequent supra- and ventricular ectopic beats
* Patients under dialysis

Primary outcomes:
measure: Measurement of the ABI
timeFrame: Day of the inclusion
Secondary outcomes:
Other outcomes:
Locations:
city: Limoges
country: France
facility: University Hospital
Study officials:
References:
Clinical trial NCT04961112: Evaluating the Efficacy of Cranial Electrotherapy Stimulation in Mitigating Anxiety-induced Cognitive Deficits
Official title: Evaluating the Efficacy of Cranial Electrotherapy Stimulation in Mitigating Anxiety-induced Cognitive Deficits
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Anxiety
Cognitive Deficit
Keywords: Cranial electrotherapy stimulation
Executive functioning
Induced Anxiety
Cognition
Threat of shock
Heart rate variability
Lead sponsor: Tufts University
Sponsor class: OTHER
First posted: 2021-07-14
Enrollment: 124
Sex: ALL
Minimum age (years): 18
Maximum age (years): 28
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: BASIC_SCIENCE

Brief summary: This study investigates the potential of cranial electrotherapy stimulation to mitigate anxiety induced cognitive deficits


Eligibility criteria: Inclusion Criteria:

* Between 18-28 years old

Exclusion Criteria:

* History of diagnosis with a neurological or psychiatric disorder.

Primary outcomes:
measure: Task switching
timeFrame: 68 weeks
measure: Working memory (N-back)
timeFrame: 68 weeks
measure: Inhibition (Stroop)
timeFrame: 68 weeks
measure: Processing speed (Simple reaction time task)
timeFrame: 68 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Medford
country: United States
facility: Tufts University
state: Massachusetts
Study officials:
References:
Clinical trial NCT04910646: The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
Official title: The Evaluation of Orange Peel Fermentation on Body Fat Lowering Efficacy in Adults
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Fat-lowering
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2021-06-02
Enrollment: 124
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Overweight and obesity can lead to the occurrence of many chronic diseases. In addition to the body mass value (BMI), the excess body fat can also be used as criteria for assessing obesity. Citrus peels are rich in many substances including limonene, Nobiletin, 3-methoxynobiletin, and flavonoids. They could be used for lowering blood pressure and reducing blood pressure, anti-anxiety and sleep aid and etc. Fermentation technology is used to ferment the peel to increase the content of neutral components in citrus peel. Therefore, I want to evaluate whether the fermented orange peel enzyme has the effect of reducing fat.


Eligibility criteria: Inclusion Criteria:

1. Adults between the ages of 20 and 65 who are willing to sign the consent form of the subject.
2. For those with BMI ≥ 24 or fatty liver, men's body fat ≥ 25%, women's body fat ≥ 30%
3. Those who are not pregnant and are willing to cooperate with contraception during the trial period.
4. Those who have no history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine disease, mental disease, alcohol or drug abuse, and other major organic diseases (according to medical history).

Exclusion Criteria:

1. Pregnant women, people with a history of cardiovascular disease, organ transplantation, epilepsy or convulsions, liver and kidney disease, malignant tumors, endocrine diseases, mental illness, alcohol or drug abuse, and other major organic diseases (according to medical history).
2. Those who had undergone major surgery or bariatric surgery (according to medical history).
3. Currently or within 3 months before participating in the screening, those subjects used drugs that can affect body fat or increase weight significantly, such as systemic corticosteroids, tricyclic antidepressants, atypical psychiatric drugs, and mood stability Drugs (according to medical history) will be excluded.

Primary outcomes:
measure: To evaluate whether the fermented orange peel enzyme has the effect of reducing fat.
timeFrame: 8 weeks
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02974712: The Effects of Two Induction Means on Emergence After General Anesthesia
Official title: The Effects of Two Induction Means on Emergence After General Anesthesia for Elderly Patients Undergoing Transurethral Endoscopic Operation
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Mean Arterial Pressure
Heart Rate
Keywords: Arterial blood gases
MAP
HR
Lead sponsor: RenJi Hospital
Sponsor class: OTHER
First posted: 2016-11-28
Enrollment: 60
Sex: ALL
Minimum age (years): 65
Maximum age (years): 79
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: This study aims to investigate the effects of different methods of administration on emergence period after laryngeal mask anesthesia in elderly patients undergoing transurethral endoscopic operation


Eligibility criteria: Inclusion Criteria:

* ASA level I or II,
* Aged from 65 to 79,
* With a duration of anesthesia \<90 min.

Exclusion Criteria:

* Chronic obstructive pulmonary diseases (COPD),
* Severe heart disease,
* Difficult airway
* Liver and kidney dysfunction,
* Cerebrovascular disease,
* Bleeding volume \>20 ml.

Primary outcomes:
measure: Mean arterial pressure (MAP)
timeFrame: One hour after surgery
Secondary outcomes:
measure: Lengths of stays in the Post anesthesia care unit(PACU)
timeFrame: One hour after surgery
Other outcomes:
Locations:
Study officials:
References: